Capital Flow Monitor · Sponsors · CIK 2091994
Dualitas Therapeutics, Inc.
681 GATEWAY BOULEVARD, SUITE 411, SOUTH SAN FRANCISCO, CA, 94080 · (917) 640-1086
Biotechnology · Corporation· inc. DELAWARE true 2023
Fit score
—
Offering
$66.6M
Sold
$32.6M
% sold
48.9%
Investors
7
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-11-18 | D ·current | 506(b) | $66.6M | $32.6M | 48.9% | 7 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Richard Murray — Executive Officer / Director, South San Francisco, CA
- Forbes Huang — Executive Officer, South San Francisco, CA
- Nikola Trbovic — Director, South San Francisco, CA
- Neil Weir — Director, South San Francisco, CA
- Alicia Levey — Director, South San Francisco, CA
- Thomas Hudson — Director, South San Francisco, CA
- Mark McDade — Director, South San Francisco, CA
- Greg Lazar — Executive Officer, South San Francisco, CA
-
Michael Ross — Director, South San Francisco, CA
1 other raise
- Therini Bio, Inc. $74.9M of $80.8M · 92.7%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.